Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)
NCT ID: NCT06243094
Last Updated: 2024-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1060 participants
OBSERVATIONAL
2024-03-12
2025-03-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care
NCT02127528
Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care
NCT05124977
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
NCT06743529
Impact of Direct Antimicrobial Susceptibility Testing on Respiratory Sample of Intensive Care Patient With Suspected VAP
NCT02897466
Impact of Antibio Prophylaxis on Occurence of Ventilator Associated Pneumonia in Trauma Patients
NCT07059039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
microbiologically confirmed VAP
patients who meet ATS/IDSA 2005 VAP criteria with microbiological confirmation
Antibiotic
All antibiotic therapy characteristics are monitored.
non microbiologically confirmed VAP
patients who do not meet ATS/IDSA 2005 criteria with microbiological confirmation
Antibiotic
All antibiotic therapy characteristics are monitored.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antibiotic
All antibiotic therapy characteristics are monitored.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission to the ICU
* Intubation and duration of invasive mechanical ventilation \> 48 hours
* Initiation of new antibiotic therapy to treat a first suspicion of Ventilator-Associated Pneumonia (VAP)
Exclusion Criteria
* Organ donor
* Prior inclusion in the study during a previous stay in the intensive care unit (a patient cannot be included multiple times)
* Participation in an interventional study focusing on the management of VAP and directly impacting antibiotic therapy practices
* Patient and/or family opposition to participation
* Lack of affiliation with a social security system
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
French Society for Intensive Care
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anahita Rouzé, MD
Role: PRINCIPAL_INVESTIGATOR
French Intensive Care Society
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lille university hospital
Lille, Haut de France, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anahita Rouzé, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01492-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.